Significant Revenue Growth
The company recorded revenue of $293,000 for Q4 2024, representing a 303% increase over Q4 2023.
Reduced Net Loss
The net loss for Q4 2024 was approximately $3.4 million, a 35% decrease from the $5.5 million net loss in the same period in 2023.
Positive Clinical Trial Results
The pivotal trial of the B-Series OCT with ImgAssist AI met its primary endpoint, achieving a statistically significant reduction in patients with residual cancer during surgery.
Premarket Approval Application Submission
The company submitted a premarket approval application to the FDA for the B-Series OCT with ImgAssist AI technology.
Expansion into New Markets
The company expanded into two new states, New Mexico and Tennessee, with its S-Series product.